• Mashup Score: 0
    Insights into mass spectrometry-based proteomics in multiple myeloma research - 6 month(s) ago

    Arun Wiita, PhD, University of California, San Francisco, CA, shares some insights into the use of mass spectrometry-based proteomics in multiple myeloma, highlighting the value of this novel approach in improving research in the field. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #IMS23 | @apwiita of @UCSF shares some insights into the value of mass spectrometry-based proteomics in multiple myeloma. Watch his interview here: 🎥 https://t.co/QMiPor6pOR @Myeloma_Society #MMsm #HemOnc

  • Mashup Score: 2
    Clinical guidance for the use of bispecific antibodies in NHL - 6 month(s) ago

    In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the unique toxicity profile associated with bispecific antibodies and provides guidance for physicians treating patients with non-Hodgkin lymphoma (NHL) using this class of agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      We recently spoke w/ Jason Westin (@Lymphoma_Doc; @MDAndersonNews), who provided clinical guidance for the use of bispecific antibodies in NHL: 🎥 https://t.co/S1PCnzbNQr #LymSM #HemOnc #ImmunoOnc #SOHO23

  • Mashup Score: 0
    Socioeconomic and racial disparities in myeloma trial recruitment - 6 month(s) ago

    Amrutha Sridhar, MBBS, University College London Hospitals, London, UK, discusses how socioeconomic and racial inequalities persist during the enrollment process in multiple myeloma clinical trials. Patients from a lower socioeconomic background are underrepresented in clinical trials, and will have worse overall survival, even after receiving treatment. Gaps in outcomes are additionally more pronounced in older patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #IMS23 | Amrutha Sridhar of @uclh discusses socioeconomic and racial disparities in myeloma trial recruitment. Watch here: 🎥 https://t.co/qjJ1tYQwT7 @Myeloma_Society #MMsm #HemOnc

  • Mashup Score: 0
    iwCLL 2023 | VJHemOnc - 6 month(s) ago

    The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be held in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over the world to discuss the latest updates in the pathobiology and treatment of CLL. The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be hel d in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Missed out on #iwCLL2023? Don't worry, we've got you covered! Our expert interviews can be found here: 🎥 https://t.co/OxDAnUzcHq #CLLsm #LeuSM #HemOnc @iwCLL https://t.co/gBpsqaitpT

  • Mashup Score: 0
    Transplant Sessions: Should patients with AML receive treatment before transplantation? | VJHemOnc - 6 month(s) ago

    Welcome to the Transplant Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). In this session, leading experts Johannes Schetelig, MD, DKMS Group and TU Dresden, Dresden, Germany, and Gesine Bug, MD, Goethe University Frankfurt, Frankfurt, Germany, discuss whether patients with acute myeloid leukemia (AML) should receive treatment before stem cell transplantation (SCT), which was presented and debated at the 2023 SOHO Annual Meeting. The experts further discuss findings

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Check out our recent session with Johannes Schetelig (@tudresden_de) & Gesine Bug (@goetheuni), who discuss whether patients with AML should be treated before SCT, the ASAP trial & more: 👉 https://t.co/3arhE4pK9A #LeuSM #BMTsm #AMLsm #HemOnc https://t.co/KA4Uv47WXF

  • Mashup Score: 0
    e-Learning Activities for Hematological Oncology - VJAcademy - 6 month(s) ago

    Explore our selection of e-learning activities designed to support the continuing education of healthcare professionals working in hematological oncology.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      NEW #CME accredited VJAcademy course on #AML 💻 🩸🔬 With leading #HemOnc experts Charles Craddock, @EuniceWangMD & @Daver_Leukemia VJAcademy is our FREE-access e-learning platform which aims to support the continuing education of #HCPs in #HemOnc💡 👉 https://t.co/18Oo9a3XEM https://t.co/3eGiZ1UuHE

  • Mashup Score: 0
    Matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA - 6 month(s) ago

    Adam Kittai, MD, Ohio State University, Columbus, OH, shares some insights into a matching-adjusted indirect comparison (MAIC) conducted using patient data from the SEQUOIA and ELEVATE-TN trials (NCT03336333; NCT02475681). Dr Kittai gives an overview of these two trials and the statistical methods used in the MAIC, and further discusses the main findings. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #iwCLL2023 | @AdamKittai of @OSUCCC_James shares some insights into a MAIC of the ELEVATE-TN and SEQUOIA trials. Watch his interview here: 🎥 https://t.co/SlKuhRHsJk @iwCLL #CLLsm #LeuSM #HemOnc

  • Mashup Score: 0
    MDS Sessions: Updates on the diagnosis, risk stratification and treatment of lower-risk MDS | VJHemOnc - 6 month(s) ago

    Hello, everyone. My name is Sanam Loghavi, I’m a hematopathologist at MD Anderson Cancer Center, and I am thrilled to be joined here today by my colleague and friend, Dr Rami Komrokji from Moffitt Cancer Center. And we’re going to speak to you about lower-risk MDS today. Thank you. It’s a pleasure to be here. So maybe I’ll start kicking off asking you some questions. As you know, I think we have…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      📣 Check out this session featuring experts @Ramikomrokji & @sanamloghavi, who give a wonderful overview of the diagnosis, risk stratification & treatment of lower-risk MDS: 👉 https://t.co/CYktMbNJ91 #MDSsm #HemOnc https://t.co/Dc5erIyzaW

Load More